Growing R&D and Demand for Point-of-Care Diagnostics Transforming the Global Cardiac Biomarkers Market

The “Global Cardiac Biomarkers Market – Outlook & Forecast 2023-2028” report has been added to’s offering.

The global cardiac biomarkers market is projected to experience robust growth, reaching $26.43 billion by 2028, with a compound annual growth rate (CAGR) of 12.14% from 2022 to 2028. This growth is attributed to several key market trends and drivers.

Key Market Trends & Drivers:

  • Integration of Multiple Cardiac Biomarkers: Healthcare professionals are increasingly combining information from various cardiac biomarkers to gain a comprehensive understanding of a patient’s cardiac health. This approach enables more accurate risk assessment, early detection of cardiovascular diseases, and personalized treatment strategies. Combining multiple biomarkers enhances patient care and improves outcomes.
  • Increasing R&D Activities: The market is witnessing a surge in research and development (R&D) activities focused on novel cardiac biomarkers. Researchers and companies are exploring innovative molecular indicators to enhance diagnostic accuracy, risk assessment, and personalized treatment strategies for cardiovascular diseases.
  • Growing Prevalence of Cardiovascular Diseases: Cardiovascular diseases (CVDs) are becoming a leading cause of global mortality, driving the demand for accurate and timely diagnosis. Cardiac biomarkers offer critical insights into heart health, enabling early detection, precise risk assessment, and effective monitoring.
  • Demand for Point-of-care Cardiac Diagnostics: Point-of-care cardiac diagnostics are gaining popularity due to their convenience and speed. Healthcare providers are adopting rapid testing methods that offer real-time cardiac insights, facilitating timely diagnosis and treatment of cardiovascular diseases.

Segmentation Highlights:

  • Biomarkers Type: Troponin, Creatine Kinase (CK-MB), Myoglobin, and Others. Troponin biomarkers, known for their specificity, accounted for the most significant market share in 2022.
  • Application: Acute Coronary Syndrome, Myocardial Infraction, Congestive Heart Failure, and Others. The acute coronary syndrome (ACS) application segment dominated the market in 2022.
  • End-user: Hospitals, Diagnostic Laboratories, and Others. Hospitals played a vital role in utilizing cardiac biomarkers for patient care in 2022.

Geographical Analysis:

  • North America: Led the market in 2022, driven by high CVD prevalence, a well-established healthcare infrastructure, and robust R&D activities, with a focus on introducing innovative biomarkers and diagnostic technologies.
  • Europe: Also contributed significantly to market growth, with Germany, France, and the U.K. as key players in introducing innovative cardiac biomarkers.
  • APAC: Including Japan, China, India, and others, is witnessing increased adoption of cardiac biomarkers in clinical practice due to rising awareness about early disease detection and prevention.

Vendor Landscape:

The global cardiac biomarkers market is highly competitive, with players ranging from pharmaceutical companies and diagnostic manufacturers to biotechnology firms and research institutions. The pursuit of improved patient outcomes and advancements in diagnostic technologies have fueled innovation and competition within the field.

Key Company Profiles

  • Abbott
  • Bio-Rad Laboratories
  • Danaher
  • F.Hoffmann-La Roche
  • PerkinElmer
  • Siemens Healthineers

Other Prominent Vendors

  • Abcam
  • bioMerieux
  • BioSupply
  • BTNX
  • CardioGenics
  • Creative Diagnostics
  • DiaSorin
  • Life Diagnostics
  • LumiraDx
  • Medix Biochemica
  • MP Biomedicals
  • Quidel
  • Randox Laboratories
  • Response Biomedical
  • Tosoh

1. How big is the global cardiac biomarkers market?
2. What is the projected growth rate of the global cardiac biomarkers market?
3. What are the rising trends in the cardiac biomarkers market?
4. Which region holds the most significant global cardiac biomarkers market share?
5. Who are the key players in the global cardiac biomarkers market?

For more information about this report visit

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other Market Reports

The global market for pain management drugs and devices was valued at $80.9 billion in 2022. The market is estimated to grow from $84.6 billion in 2023 at a compound annual growth rate (CAGR) of 5.4% to reach approximately $109.9 billion by the end of 2028. This report segments the global market by product, application and region.
The global market for Medical Imaging Equipment Services estimated at US$20.9 Billion in the year 2022, is projected to reach a revised size of US$29.7 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2022-2030.
The healthcare sector has witnessed remarkable changes in the last decade. There has been an increase in the usage of innovative and sensitive diagnostic tools, and this is resulting in advancements in healthcare facilities. The evolution of imaging technology has contributed to the development of better diagnoses and clinical interventions.
The global hernia mesh devices market size is expected to reach USD 8.32 billion by 2030, registering a CAGR of 6.7% during the forecast period. The growth is owing to an increase in the incidence of hernias, and the high adoption of meshes in surgeries due to factors such as reduced operative time, cost-effectiveness, reduced pain, and high availability of products in the market.

By using this website you agree to accept Medical Device News Magazine Privacy Policy